ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Lung Cancer trials near Madrid, MD, ESP:

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 83 other locations

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Trastuzumab deruxtecan

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 49 other locations

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: MGY825

Phase 1

Novartis
Novartis

Madrid, Spain and 12 other locations

to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: JDQ443
Drug: docetaxel

Phase 3

Novartis
Novartis

Madrid, Spain and 54 other locations

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 209 other locations

locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (CTM-1 Lyo-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 21 other locations

the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Madrid, Spain and 30 other locations

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...

Enrolling
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
Drug: ELVN-002
Drug: Trastuzumab emtansine

Phase 1

Enliven Therapeutics

Madrid, Spain and 38 other locations

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 123 other locations

in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...

Enrolling
Extensive Stage-small Cell Lung Cancer
Drug: Ifinatamab deruxtecan
Drug: Carboplatin

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 48 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems